Hester Biosciences Ltd.
| BSE: 524669 | Sector: Health care |
| NSE: HESTERBIO | ISIN Code: INE782E01017 |
| BSE 00:00 | 16 Apr | 2349.45 |
336.45 (16.71%) |
OPEN
2051.00 |
HIGH
2401.45 |
LOW
2039.65 |
| NSE 00:00 | 16 Apr | 2343.85 |
329.90 (16.38%) |
OPEN
2069.00 |
HIGH
2399.90 |
LOW
2013.95 |
| OPEN | 2051.00 |
| PREVIOUS CLOSE | 2013.00 |
| VOLUME | 13649 |
| 52-Week high | 2401.45 |
| 52-Week low | 980.00 |
| P/E | 55.45 |
| Mkt Cap.(Rs cr) | 1,999 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Hester Biosciences Ltd. (HESTERBIO) - News Sector
-
Stocks picks by Osho Krishan: Buy Adani Enterprises, Godrej Consumer
8.13 am | 16 Apr 2021 | Business Standard
The mean of the Bollinger band has historically proven strong support for Adani Enterprises, making it a favourable risk-reward ratio for a short-term...
-
Domestic growth trajectory to remain strong for Glenmark in near term
10.49 pm | 15 Apr 2021 | Business Standard
Debt reduction key if the stock is to fetch higher valuation multiples
-
Jhunjhunwala trims stake in Titan, 2 others in Q4; buy Fortis Healthcare
2.56 pm | 15 Apr 2021 | Business Standard
During the March quarter of the financial year 2020-21 (Q4FY21), Rakesh Jhunjhunwala offloaded a 0.26 percentage point stake, or 2.25 million shares, ...
-
Dr Reddy's to also use govt cold chain infra for Sputnik V distribution
11.26 am | 15 Apr 2021 | Business Standard
The vaccine would be transported in frozen form by air and road
-
Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh
11.34 pm | 13 Apr 2021 | Business Standard
Access to the private market, international sales are other factors that will impact margins
-
Dr Reddy's to submit more data on Covid-19 vaccine Sputnik V by July
1.09 am | 13 Apr 2021 | Business Standard
Colour-coded doses will have two different antigens
-
Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use
3.57 pm | 12 Apr 2021 | Business Standard
This is the third vaccine approved by India, after Covishield and Covaxin.
-
Anupam Rasayan rebounds 13% from day's low on repaying debt worth Rs 471 cr
3.02 pm | 12 Apr 2021 | Business Standard
The debt repayment will result in significant savings in the finance cost, it said
-
Solara Active Pharma extends gains, rallies 12% on merger with Aurore Life
12.12 pm | 12 Apr 2021 | Business Standard
Solara Active and Aurore Life Sciences' amalgamation would create one of the largest API players in the industry
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
11.02 am | 12 Apr 2021 | Business Standard
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
-
Nifty outlook and stock picks by Sameet Chavan: Buy Balrampur Chini, Pfizer
8.57 am | 12 Apr 2021 | Business Standard
The deciding factor in days to come has to be the financial space
-
Cyclical sectors are expected to drive March 2020 quarter earnings growth
8.31 am | 12 Apr 2021 | Business Standard
Bank results are especially eagerly awaited in this quarter. The Supreme Court has lifted its stay order, which means that banks can report NPAs reali...
-
Here is a Bull Spread Strategy on Glenmark Pharma by HDFC Securities
8.28 am | 9 Apr 2021 | Business Standard
The stock price has already given bullish breakout from the downward slopping trendline adjoining the highs of 08-Dec-2020 and 12-Jan-2021
Quick Links for Hester Biosciences:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
